Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Document › Details

Lonza Group Ltd.. (5/22/18). "Press Release: Lonza Further Strengthens Hepatocytes Portfolio with Addition of Hepatic Non-Parenchymal Cells". Basel.

Organisations Organisation Lonza Cologne GmbH
  Group Lonza Group (Group)
  Organisation 2 Lonza Group AG
  Today Lonza Group (Group)
  Group Lonza Group (Group)
Product Product ADME technology
Persons Person Bunger, Maureen (Lonza 201703 Product Manager ADME-Tox Solutions)
  Person 2 Haberkamm, Petra (Lonza 201703 Manager Marketing Communcations at Lonza Cologne GmbH)
     


Today Lonza announced the addition of hepatic stellate cells, Kupffer cells and liver-derived endothelial cells to its extensive hepatocytes portfolio. These hepatic non-parenchymal cells provide scientists with the building blocks to create more physiologically relevant in vitro models, including cocultures and 3D cell cultures, for enhanced liver disease research.

Hepatic non-parenchymal cells are involved in normal liver function, including transport, metabolism and growth; however, they also play important roles in the immune response. Kupffer cells, for instance, are the resident macrophages of the liver and are one of the first lines of defense against bacteria and toxins in the gut. In addition, liver-derived endothelial cells form the primary cellular barrier that lines blood vessels and sinusoids in the liver.

As well as their role in normal liver function, hepatic nonparenchymal cells can be involved in the formation of common liver diseases. For example, when the liver is damaged, stellate cells can differentiate to form myofibroblasts, leading to collagen deposition, which can result in cirrhosis. Therefore, by creating more sophisticated in vitro culture models that incorporate both hepatocytes and non-parenchymal cells, scientists can improve the translatability of their toxicity testing and pharmacokinetics studies to clinical trials, thus aiding the development of new liver disease treatments.

The expansion of Lonza’s hepatocytes portfolio illustrates its continued commitment to providing the pharmaceutical industry with high-quality primary cells and further strengthens Lonza’s position as a leading provider of hepatocytes and ADME-Tox products. By now offering all four major liver cell types (hepatocytes, stellate cells, Kupffer cells and liver-derived endothelial cells), Lonza offers a one-stop shop for scientists looking to source human liver cells for their drug discovery research.

“Researchers working in drug metabolism, hepatitis, NASH, and other liver diseases with complex involvement of different liver cell types are trending toward using more physiologically relevant cell models,” said Dr. Maureen Bunger, Product Manager for ADME-Tox Solutions at Lonza. “Our high-quality hepatic non-parenchymal cells are isolated and enriched from human liver tissue. They are precharacterized for a variety of different applications, such as post-thaw plating, morphology and response to LPS stimulation, which saves researchers both time and money by reducing the need to evaluate cells for experiments.”

More information about Lonza’s comprehensive hepatic non-parenchymal cell portfolio is available on the Lonza website: Ť
https://www.lonza.com/products-services/bioresearch/adme-tox/hepatic-non-parenchymal-cells.aspx


About Lonza

Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment.

Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fastmoving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.

Founded in 1897 in the Swiss Alps, Lonza today is a wellrespected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com


Lonza Contact Information

Lonza Cologne GmbH
Manager Marketing Communications
Petra Haberkamm
Tel +49 221 991990
petra.haberkamm@lonza.com

Lonza Group Ltd
Head External Communications
Constance Ward
Tel +41 61 316 8840
constance.ward@lonza.com


Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.


Lonza Ltd
Muenchensteinerstrasse 38
CH-4002 Basel, Switzerland
+41 61 316 81 11
+41 61 316 91 11
media@lonza.com

   
Record changed: 2018-05-23

Advertisement

Picture [iito] – Putting Information into Context 600x60px

More documents for Lonza Group (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px




» top